The significant reduction in mortality and cardiovascular events from the HELIOS-B Phase 3 study results is a positive development for Alnylam Pharmaceuticals. This could lead to increased investor confidence and a potential rise in stock price. The upcoming conference call and investor webcast will likely provide further details, potentially driving short-term interest and stock movement.